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Therapy resistance is crucial for the high mortality of melanoma. The death ligand tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) bears high potential as a new anticancer agent, as binding to the death recep-
tors TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4) or TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5) trig-
gers apoptosis in most cancer cells. For melanoma, however, only a weak responsiveness of primary cultures was
reported, and in particular the role of DR4 was neglected. For evaluating melanoma susceptibility we studied the
functionality of DR4 and DR5 in melanoma cells as well as their expression in vivo. DR5 was consistently expressed
in melanoma cell lines, whereas DR4 was found in only 2/7 cell lines. High sensitivity to TRAIL-induced apoptosis
was characteristic for DR4-positive melanoma cells, whereas DR4-negative cells showed less and delayed re-
sponse or were resistant. The use of selective DR4/DR5 blocking antibodies unequivocally proved the prevalent
role of DR4 in those melanoma cells, where it was expressed. The significance of these data for the in vivo situation
was ﬁnally evaluated by immunohistochemistry, which proved pronounced expression of DR4 as well as of DR5 in
melanoma primary tumors. Thus, DR4 expression in vivo and the high efﬁciency of DR4-mediated apoptosis may
suggest reassessment of the suitability of TRAIL and especially of DR4-based strategies for melanoma treatment.
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Melanoma of the skin is characterized by unbroken high
mortality and increasing incidence rates in the last decades
(Lens and Dawes, 2004). Of major importance is a high
metastatic potential as well as apoptosis resistance, which
substantially contribute to immune escape mechanisms
and to inefficiency of chemotherapeutics (Igney and
Krammer, 2002). Overcoming apoptosis resistance, there-
fore, is a challenge for developing new therapeutic strate-
gies against cancer. For melanoma, in several experimental
models, we have shown that triggering of apoptotic cas-
cades, especially by overexpression of proapoptotic genes,
provides an efficient targeting strategy (Eberle et al, 2003;
Hossini et al, 2003; Bektas et al, 2005; Fecker et al, 2005).
Apoptosis is a well-defined genetic death program lead-
ing to ordered destruction of cellular components while
membrane integrity is maintained. Two major pathways
have been described that activate aspartate-specific
cysteine proteases (caspases) representing major effectors
in realization of apoptosis. The intrinsic pathway, also ac-
tivated by chemotherapeutic drugs, depends on intracellu-
lar signals such as DNA damage, mitochondria, and the
tumor suppressor p53. On the other hand, the extrinsic
pathway is initiated by specific binding of death ligands to
cell surface death receptors and formation of the death-
inducing signaling complex (DISC), which triggers activation
of the caspase cascade (Riedl and Shi, 2004)
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/APO2L) belongs to the Tumor necrosis factor (TNF)
superfamily and binds to its death receptors TRAIL-R1/DR4
(death receptor 4) and TRAIL-R2/DR5 (death receptor 5)
(Pan et al, 1997; Walczak et al, 1997). This results in re-
ceptor oligomerization, DISC formation, and subsequent
activation of initiator caspase-8 and -10. Effector caspases
such as caspase-3 are either directly activated by caspase-
8, or this caspase cleaves and activates the proapoptotic
Bcl-2-related protein Bid, which delivers the signal further
downstream to the mitochondria and thus connects the two
major pathways (LeBlanc and Ashkenazi, 2003).
The particular significance of TRAIL for clinical strategies
results from its advantage to target tumor cells, whereas
most non-malignant cells were largely protected (Yagita
et al, 2004). Preclinical studies already demonstrated the
high potential of TRAIL in mice and in primates, when used
as a single agent or in combination with chemotherapeutic
drugs. Suppression of tumor xenografts without obvious
signs of systemic toxicity qualified TRAIL as a promising
strategy for cancer therapy (Walczak et al, 1999; Shankar
et al, 2005). For selective receptor targeting, recombinant
TRAIL derivatives as well as agonistic monoclonal DR4 and
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DR5 antibodies have been developed, and have also been
tested to be efficient in mice (Takeda et al, 2004; Kelley et al,
2005).
Targeting of tumors by TRAIL or agonistic antibodies
basically depends on the functionality of the respective re-
ceptors. Unlike other tumors with a predominant signifi-
cance of DR4 (Strater et al, 2002; Kazhdan and Marciniak,
2004), TRAIL sensitivity of melanoma is presently believed
to mainly depend on DR5, whereas the biological signifi-
cance of DR4 in melanoma was so far neglected (Zhang
et al, 1999; Hersey and Zhang, 2001; Zhang et al, 2004).
Furthermore, in primary cultures of melanomas, pro-
nounced TRAIL resistance in parallel to downregulation of
DR5 has been reported (Nguyen et al, 2001), which would
not support application of available TRAIL-based strategies
in melanoma patients.
The aim of this investigation was to clarify the function-
ality of DR4 and DR5 for TRAIL-induced apoptosis in me-
lanoma. Melanoma cell lines and cultures of normal human
melanocytes were investigated in terms of TRAIL sensitivity,
expression and functionality of death receptors and activa-
tion of the engaged pathways. Contrary to previous inter-
pretations, DR4 turned out as a major player for TRAIL
sensitivity in melanoma cells, as DR4 mediated even higher
sensitivity than DR5. The clinical significance of these find-
ings was finally substantiated by positive immunohisto-
chemical staining for both DR5 and DR4 in the vast majority
of investigated melanoma sections.
Results
Consistent expression of DR5 but selective expression
of DR4 in melanoma cells lines To an overview about the
expression level of TRAIL death receptors, fluorescence-
activated cell sorting (FACS) analyses for DR4 and DR5
were performed in a panel of seven human melanoma cell
lines and three cultures of normal human melanocytes
(NHM). Whereas the surface expression of DR5 was con-
sistently found in all melanoma cell lines, analyzed, signif-
icant DR4 expression was seen in only two of them (A-375
and SK-Mel-13). Normal melanocytes showed only a weak
expression of DR5 and were negative for DR4 (Fig 1A, B).
The FACS data were confirmed by western blot analyses
of the seven melanoma cell lines and of five NHM. In all cell
Figure 1
Melanoma cell lines subdivide into positive and negative for death
receptor 4 (DR4). (A) Surface expression of DR4 and death receptor 5
(DR5) was analyzed by fluorescence-activated cell sorting analysis in
seven human melanoma cell lines and in cultures of normal human
melanocytes (NHM). Median values obtained for melanoma cell lines
(two independent experiments) and for NHM (three independent cul-
tures) were normalized with respect to the negative control (primary
antibody omitted). Dark bars are representative for DR4 and white bars
for DR5, respectively. (B) Examples of DR4-positive cell lines (A-375,
SK-Mel-13) and of DR4-negative cells (Mel-HO, SK-Mel-23) as well as
of NHM are given. Cells were labeled with specific monoclonal (TRAIL)-
R1/DR4 and TRAIL-R2/DR5 antibodies (filled graphs) as well as with an
isotypic control IgG1 mouse monoclonal antibody (open graphs), re-
spectively. A shift to the right side indicates death receptor surface
expression. (C) Preparations of total protein of seven melanoma cell
lines and of five cultures of NHM were analyzed by western blotting for
DR4 and DR5 expression. Equal protein amounts (25 mg per lane) were
separated by SDS-PAGE. Consistent blotting was proven by Ponceau
staining and by evaluation of b-actin expression. Arrows indicate mo-
lecular weights of identified protein bands. A highly comparable pattern
of protein bands was obtained in a second experiment started from
independently grown cell cultures. (D) SK-Mel-13 cells transiently
transfected with two different concentrations of DR4 and DR5 expres-
sion plasmids (SKM-13a: 0.1 mg per mL; SKM13b: 0.2 mg per mL) were
investigated 48 h after transfection by western blot analysis for DR4
and DR5 (SDS-PAGE, 40 mg total protein per lane). Expression was
compared with the basic expression in untransfected SK-Mel-13 and
A-375 cells. Two independent series of transfection experiments have
been performed, which revealed the same result.
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lines, the DR5 antibody identified two protein bands corre-
sponding to 40 and 47 kDa molecular weight with a ten-
dency toward upregulation of DR5 in melanoma cells. DR4
antibody revealed several weak protein bands between 50
and 60 kDa, which were ubiquitously expressed and were
regarded as unspecific. Only a 44 kDa protein obtained in A-
375 as well as in SK-Mel-13 corresponded well with the
positive FACS data (Fig 1C).
To demonstrate the specificity of the identified protein
bands, SK-Mel-13 was transiently transfected with plasm-
ids containing full-length cDNA of DR4 and DR5, respec-
tively. Considerable increase of the 44 kDa protein after
transfection of DR4 as well as of the 47 kDa protein after
transfection of DR5 proved the identity of these protein
bands for the respective death receptors in melanoma cells
(Fig 1D).
High sensitivity to TRAIL-mediated apoptosis in DR4-
positive melanoma cell lines For investigating possible
correlations between receptor expression and responsive-
ness to TRAIL-mediated cell death, the relative apoptosis
and cytotoxicity values were determined by measuring DNA
fragmentation and lactate dehydrogenase (LDH) release,
respectively. Cells were analyzed at three different times (6,
24, and 48 h) after addition of TRAIL (20 ng per mL and 100
ng per mL). Both DR4-positive melanoma cell lines (A-375
and SK-Mel-13) showed highest sensitivity already after 6 h,
whereas of the five melanoma cell lines lacking DR4, only
two (Mel-HO and SK-Mel-19) showed a (weaker) apoptotic
response at this early time. Apoptosis rates increased after
24 h in Mel-HO and (less) in SK-Mel-19, in clear contrast to
A-375 and SK-Mel-13, for which the rate of DNA fragmen-
tation already started to decline after 6 h. The cell lines SK-
Mel-23 and Mel-2a as well as normal melanocytes showed
a rather limited response detectable only after 48 h, where-
as MeWo was completely resistant over the period of ob-
servation (Fig 2A).
No increase of cytotoxicity due to TRAIL treatment was
seen after 6 h, but followed induction of apoptosis with
temporary distance, indicating that the primary effect of
TRAIL was apoptosis (Fig 2B). Thus, melanoma cell lines
expressing DR4 in addition to DR5 were highly responsive
to TRAIL, whereas DR5 alone mediated a weaker and de-
layed apoptotic response.
Strong activation of apoptosis cascades in DR4-positive
melanoma cells For obtaining insight into the pathways of
TRAIL-mediated apoptosis in melanoma cells with regard to
their expression of death receptors, cleavage of caspase-8,
-10, -9, -3, and -7, Bid, XIAP (X-linked inhibitor of apoptosis
protein), and DFF45 was monitored in the panel of seven
melanoma cell lines after treatment with 20 ng per mL TRAIL
for 4 h. The sensitive melanoma cell lines (A-375, SK-Mel-
13, Mel-HO, and SK-Mel-19) showed caspase-8 cleavage
after TRAIL induction into its intermediate and final products
(43/41, 18 kDa) (Fig 3). Expression of caspase-10 was
identified in all investigated melanoma cell lines, except for
MeWo, at molecular weights of 59, 55, and 30 kDa likely
corresponding to isoforms described previously in lymph-
oma and Jurkat cells (Sprick et al, 2002). Degradation of
Figure 2
High sensitivity of (TRAIL)-induced
apoptosis. Seven melanoma cell lines
as well as normal human melanocytes
(NHM) were treated with 20 ng per mL
TRAIL (gray bars) and with 100 ng per mL
(black bars), respectively. After incubation
times of 6, 24, and 48 h, the relative DNA
fragmentation rates indicative for apopto-
sis (A) and relative lactate dehydrogenase
activities in cell supernatants indicative
for cytotoxicity (B) were determined. Un-
treated controls (white) line were individ-
ually for each cell to 1. Mean values and
standard deviations of three independent
experiments each performed with double
values are shown.
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caspase-10 after TRAIL induction was significant in A-375,
with a similar tendency in SK-Mel-13. In contrast, there
was no evidence of caspase-10 cleavage after 4 h in the
melanoma cell lines lacking DR4.
Whereas the p20 intermediate cleavage product of the
main effector caspase-3 was found in all melanoma cell
lines after TRAIL treatment, the 17 kDa mature product (Han
et al, 1997) selectively appeared in the sensitive cell lines A-
375, SK-Mel-13, Mel-HO, and SK-Mel-19. The intensity of
the 17 kDa protein as determined by western blot 4 h after
TRAIL treatment showed tight correlation with the apoptotic
response of the cells 6 h after treatment (Figs 2 and 3).
Largely in parallel with caspase-3 activation, cleavage of
caspase-7 and of the death substrate DFF45 occurred. Al-
so, the 29 kDa cleavage product of XIAP was seen in sen-
sitive melanoma cells, most prominently in A-375. Cleavage
of XIAP, however, did not result in its significant reduction
after 4 h (Fig 3).
The basic expression level of initiator caspases seemed
to be critical for efficient DISC formation in DR4-negative
melanoma cells. Caspase-8 and -10 were expressed in
melanoma cell lines to varying degrees; however, sensitive
Mel-HO cells lacking DR4 expression were characterized by
highest expression levels of both initiator caspases, where-
as expression of initiator caspases was rather weak in SK-
Mel-13. On the other hand, high caspase-8 or caspase-10
levels were not sufficient for supporting TRAIL sensitivity in
SK-Mel-23 and Mel-2a (Fig 3).
Clear signs for activation of the mitochondrial pathway
were seen in A-375 as degradation of the proform of Bid
and as occurrence of the 37 kDa cleavage product of ca-
spase-9 (Fig 3). On the other hand, SK-Mel-13 and DR4-
negative melanoma cell lines did not reveal any degradation
of Bid, and also revealed weaker activation of caspase-8
and -9, what may be seen as an indication for additional
alternative pathways also in TRAIL-induced apoptosis.
For further assessing the implications of the mi-
tochondrial pathway for TRAIL-induced apoptosis in me-
lanoma, stably transfected cell clones of A-375 and Mel-HO
highly overexpressing Bcl-2 were evaluated with respect to
TRAIL sensitivity. Apoptosis induction by TRAIL was com-
pletely suppressed by overexpression of Bcl-2 in both cell
clones, as compared with mock-transfected cells (Fig 4A,
B). In SK-Mel-13 cell clones stably transfected with Bcl-xL
functionally related to Bcl-2 (SKM-13-Bcl-xL11, SKM-
13-Bcl-xL15), overexpression of Bcl-xL resulted in 2.6 
0.3-fold, respectively, 2.1  0.4-fold reduction of TRAIL-in-
duced apoptosis as compared with mock-transfected cells
(Fig 4c). In parallel with these data, transient transfection of
SK-Mel-13 with a Bcl-2 expression plasmid resulted in
1.6  0.3-fold reduction of TRAIL-induced apoptosis (data
not shown). Thus, the mitochondrial pathway seemed to
exert at least contributory functions for TRAIL-induced
apoptosis in SK-Mel-13, whereas it was revealed as es-
sential in A-375 and in Mel-HO.
Prevalence of DR4 for TRAIL-induced apoptosis in cell
lines expressing both receptors For investigating the re-
spective contribution of both death receptors to TRAIL-me-
diated apoptosis, cells were treated with monoclonal
antibodies blocking DR4 or DR5 selectively. When apply-
ing DR4 antibodies, apoptosis was largely blocked in A-375
(70%) and in SK-Mel-13 (83%) after 6 h, whereas the effect
of DR5 antibodies was less pronounced in these cell lines
(23% and 44% inhibition, respectively). Almost complete
reduction was seen when both antibodies were applied
(96%; Fig 5).
Application of DR5 blocking antibodies alone resulted in
a significant increase of apoptosis in all the melanoma cell
lines investigated, most pronounced in Mel-HO, indicative
of an agonistic side effect caused by this antibody. There-
fore, for the calculation of its antagonistic effect, the values
were normalized for the agonistic side effect. According to
this normalization, DR5 blocking antibodies were able to
prevent apoptosis in Mel-HO to 84% and in SK-Mel-19%
to 91%. DR4 antibodies remained without any effect in
these cell lines (Fig 5). Cytotoxicity monitored in parallel did
not reveal any significant changes in melanoma cells after 6
h (data not shown). These experiments clearly indicate that
blocking DR5 worked efficiently but exerted only a minor
effect on melanoma cells expressing DR4.
The DR4-positive cell lines A-375 and SK-Mel-13 were
further used in western blot experiments after applying
TRAIL in combination with the two different blocking
Figure 3
Strong caspase activation in death receptor 4 (DR4)-positive me-
lanoma cells. Western blot experiments for capase-8, -10, -9, -3, -7,
Bid, XIAP, and DFF45 are shown for seven investigated melanoma cell
lines. Proteins were extracted from cultures 4 h after TRAIL treatment
(þ ) and from parallel controls (). For caspase-8 and XIAP, two dif-
ferent exposure times were selected for visualization of the uncleaved
and the cleaved forms, respectively. Equal amounts of proteins (25 mg
per lane) were loaded, and consistent blotting was proven by Ponceau
staining and by evaluation of b-actin expression. Molecular weights of
proforms and cleavage products are indicated. Two experiments per-
formed for each cell line starting from independent cultures revealed
highly similar results.
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antibodies. In full agreement with the results from the
apoptosis assays, blocking DR4 strongly diminished the
occurrence of cleavage products for caspase-8, -3 and -7 in
A-375 and in SK-Mel-13. Similarly, reduction of Bid as well
as occurrence of the 29 kDa XIAP cleavage product and of
DFF45 were almost prevented. In contrast, the effects of
blocking DR5 were much less pronounced, clearly proving
the prevalent role of DR4 for TRAIL-induced apoptosis in
these cells (Fig 6).
Significant expression of DR4 and DR5 in primary me-
lanomas In order to assess the significance of functional
DR4 in melanoma cell lines for the clinical situation, ex-
pression of DR4 and DR5 was investigated by immuno-
histochemistry in biopsies of 40 patients with nodular or
superficial-spreading melanoma (tumor thickness: 1.5–4.0
mm). Of the 40 primary tumors examined, 32 (80%) re-
vealed significant expression of both receptors, in 4 tumors
(10%), expression for both receptors was weak or almost
negative, and in other 4 tumors either DR4 or DR5 was lost
(Fig 7).
Specificity of the antibodies applied was proven by
immunocytochemistry of melanoma cell lines A-375, SK-
Mel-13, and SK-Mel-23. In full agreement with FACS anal-
ysis detailed in Fig 1, immunocytochemistry for A-375 and
for SK-Mel-13 revealed positivity for DR4 and for DR5,
whereas SK-Mel-23 was negative for DR4 but positive for
DR5 (Fig 7). These data clearly indicate that expression of
DR4 was as frequent as DR5 in melanoma, possibly indic-
ative of the significance of both receptors in melanoma
patients.
Discussion
The compelling advantage of TRAIL to trigger apoptosis in a
variety of human cancer cells, whereas normal cells and
tissues were largely spared (Yagita et al, 2004), is highly
suggestive for using TRAIL in experimental tumor therapies.
The tumor toxic effect requires selective binding of TRAIL to
one of its agonistic receptors (DR4 or DR5), and thus is
highly dependent on their functionality in the target cell. An
increased expression of agonistic TRAIL receptors in can-
cer cells has been attributed to their higher sensitivity (Ryu
et al, 2000; Koornstra et al, 2003). DR5 was found in various
tumor cells, but DR4 was often lacking in resistant cells (Kim
et al, 2000). For melanoma, the majority of cell lines were
reported as positive for DR5, whereas DR4 was often lost
(Zhang et al, 1999, 2000a).
In agreement, here we show consistent surface expres-
sion of DR5 in 7 melanoma cell lines and in cultures of
normal human melanocytes, whereas significant expression
of DR4 was found only in two of the melanoma cell lines, as
determined by FACS analysis. Comparison of the surface
expression data with western blot analyses from total pro-
tein extracts revealed protein bands for DR5, largely in
Figure 4
TRAIL-induced apoptosis is reduced after overexpression of Bcl-2 and Bcl-xL. (A, B) Melanoma cell clones stably transfected with Bcl-2 (A-
375/Bcl-2 and Mel-HO/Bcl-2) or transfected with vector DNA (A-375/mock and Mel-HO/mock) were treated for 24 h with 20 ng per mL TRAIL (gray
bars) and 100 ng per mL (black bars), respectively. Relative values for DNA fragmentation were normalized to the respective untreated mock cells
(set to 1). The experiment was performed twice with double values each time, means and standard deviations for all 4 values are given here. (C) SK-
Mel-13 cell clones stably transfected with Bcl-xL (SKM-13-Bcl-xL11 and SKM-13-Bcl-xL15), respectively, transfected with vector DNA (SKM-13-
mock) were used. Cells were treated as described above for 24 h with 20 ng per mL TRAIL (gray bars) or left untreated (white bars). Untreated mock
cells were set to 1. Cells were investigated under inducible conditions (2 mg per mL doxycycline). Means and standard deviations of two independent
experiments are given, each consisting of triple values (six values). (D) Expression of Bcl-2 in mock respectively in Bcl-2-transfected cells as
determined by western blot analysis. E) Expression of Bcl-xL in mock, respectively, in Bcl-xL-transfected cells as determined by western blot
analysis. Expression is induced in these clones by doxycycline (Dox). Western blot experiments were performed twice resulting in largely identical
results.
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agreement with previous reports on hepatocellular carcino-
ma, lymphoma, and Jurkat cells (Bodmer et al, 2000; Hi-
guchi et al, 2001). For DR4, however, the situation was less
clear, as protein bands of highly varying size had been re-
ported, in particular, of roughly 57 kDa (Higuchi et al, 2001;
Matysiak et al, 2002; Song et al, 2003). For our panel of
melanoma cell lines, we found only weak signals at this
molecular weight, which, furthermore, did not show any
correlation to the FACS expression data. Correlation to
FACS analysis, however, was seen for a 44 kDa protein,
strongly suggesting that this protein may correspond to
DR4 in melanoma cells. A protein of similar molecular
weight has also been reported in HeLa cells (Lichtenstein
et al, 2004). The specificity of the 44 kDa protein of DR4 and
of the 47 kDa protein of DR5 was unequivocally proven here
for melanoma cells by transient transfection of the respec-
tive cDNA. As the 44 kDa band of DR4 was in question, after
these experiments, it became clear that this protein size
indeed corresponds to DR4 in melanoma cells.
Both agonistic receptors might equally contribute to
TRAIL-mediated apoptosis in certain cells; however, due to
the correlation between expression and sensitivity data or
due to applying selective recombinant TRAIL or selective
antagonistic antibodies, the prevalent role of either one or
the other death receptor has been proposed. For untrans-
formed cells as for fibroblasts, a prevalent role of DR5 has
been postulated (Ichikawa et al, 2003), whereas TRAIL sen-
sitivity was proven to mainly result from DR4 in oligoden-
drocytes and in keratinocytes (Matysiak et al, 2002;
Leverkus et al, 2003). For tumor cell lines, several reports
suggested a major contribution of DR4 in cells from lung,
colon, and breast carcinoma (Kim et al, 2000; Strater et al,
2002; Kazhdan and Marciniak, 2004; Jin et al, 2004). A re-
cent study, however, may also suggest DR5 as a main ef-
fector for TRAIL-induced apoptosis in several cancer cell
lines (Kelley et al, 2005).
For melanoma cells and normal melanocytes, DR5 has
especially been regarded as critical for TRAIL-induced
apoptosis (Zhang et al, 1999, 2000b, 2004; Hersey and
Zhang, 2001). This may partly result from the fact that sev-
eral TRAIL-sensitive melanoma cell lines were characterized
by high levels of DR5. No clear correlation, however, be-
tween sensitivity and expression levels of DR5 could be
found (Zeise et al, 2004), which may be indicative of a high
impact of intracellular regulation mechanisms such as re-
ported for cFLIP, inhibitors of apoptosis (cIAP), and NF-kB
(Hussein et al, 2003). Functional studies on the contribution
of DR4 in melanoma, however, are few. Only two melanoma
Figure 5
Blocking death receptor 4 (DR4) prevents apoptosis in melanoma
cells positive for both receptors. Subconfluent cultures of four me-
lanoma cell lines were pre-incubated for 1 h with blocking antibodies
for DR4 and DR5, respectively, before starting treatment with TRAIL
(20 ng per mL, for another 6 h). Relative values for DNA fragmentation
were calculated with respect to the basic apoptotic rates determined
for untreated controls (set to 1, separately for each cell line). Mean
values and SD of three independent experiments (A-375, SK-Mel-13)
and of two experiments (Mel-HO, SK-Mel-19) are shown, each exper-
iment itself consisted of triple values.
Figure6
Block of apoptotic cascades by death receptor 4 (DR4) antagonists
in A-375 and SK-Mel-13. Western blot analysis for capase-8, -3 and -7
as well as for XIAP and DFF45 are shown for A-375 and SK-Mel-13.
Cells were pre-incubated with blocking antibodies for 1 h before start-
ing TRAIL treatment (20 ng per mL, for another 4 h). Equal amounts of
proteins (25 mg per lane) were loaded, and consistent blotting was
proven by Ponceau staining and by evaluation of b-actin expression.
The experiment was performed twice starting from independent cul-
tures, and revealed highly comparable results.
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cell lines have been submitted to functional analyses
applying specific DR4 blocking antibodies, as reported in
the literature. In one cell line, this treatment remained with-
out effect (Griffith et al, 1999). The reduction of TRAIL sen-
sitivity observed in the other cell line was explained as a
result of DR4-mediated downregulation of TRAIL decoy re-
ceptors (Zhang et al, 2000a). The significance of decoy re-
ceptors for regulation of TRAIL sensitivity in melanoma cell
lines, however, remains elusive (Zhang et al, 1999; Zeise
et al, 2004). Here, we found that melanoma cell lines pos-
itive for both DR5 and DR4, as characterized unequivocally
by FACS analysis, immunocytochemistry, and western blot
analysis, revealed highest sensitivity to TRAIL-induced
apoptosis already after 6 h, whereas melanoma cell lines
lacking DR4 showed reduced and time-delayed sensitivity
or remained largely resistant.
Clear signs of apoptosis, in particular, activation of ca-
spases, were seen in all sensitive melanoma cells. In the
course of TRAIL-induced apoptosis, only the mature p17
cleavage product of caspase-3 (Han et al, 1997) correlated
with TRAIL sensitivity, whereas the intermediate product p20
was seen in all—sensitive and resistant—melanoma cell
lines. This might indicate some caspase-3 cleavage
also induced in resistant cells, but the final step leading to
mature caspase-3 seemed to be restricted to sensitive cells.
Selective cleavage of p17 has also been reported for another
TRAIL-sensitive melanoma cell line (Zhang et al, 2001).
Degradation of the caspase-inhibitory protein XIAP has
been regarded as critical for TRAIL-induced apoptosis in
melanoma (Zhang et al, 2001). Cleavage products of XIAP
were also seen in this investigation early after TRAIL treat-
ment; however, cleavage was not sufficient as to reduce
basic XIAP levels significantly after 4 h. Thus, for early
TRAIL-mediated apoptosis (after 6 h), degradation of XIAP
seemed to be less responsible in melanoma cells.
In agreement with our previous findings regarding the
significance of the mitochondrial pathway for CD95/Fas-
mediated apoptosis in melanoma (Raisova et al, 2001;
Eberle et al, 2003), clear characteristics of the mitochondrial
pathway were also seen in A-375 upon TRAIL-mediated
apoptosis, namely, cleavage of caspase-9 and Bid. Fur-
thermore, apoptosis was completely blocked in A-375 and
Mel-HO after stable overexpression of Bcl-2. On the other
hand, TRAIL-induced apoptosis was only partially blocked
in SK-Mel-13 after transient overexpression of Bcl-2 or after
stable overexpression of Bcl-xL. The fact that SK-Mel-13
revealed no cleavage of BID as well as only a weaker
cleavage of caspases may be seen as an indication for ad-
ditional alternative pathways also in TRAIL-induced apop-
tosis. Nevertheless, the mitochondrial pathway seemed to
exert at least contributory functions for TRAIL-induced
apoptosis in SK-Mel-13, and it was revealed as essential in
A-375 and in Mel-HO.
The crucial question of the relative contribution of the
two TRAIL death receptors has been addressed in this
study by utilizing monoclonal antibodies blocking either one
of the two. The specificity of these antibodies to bind and
block their appropriate target has been shown previously
(Sprick et al, 2002; Leverkus et al, 2003). Here, blocking of
DR4 almost prevented TRAIL-induced apoptosis in me-
lanoma cells positive for both death receptors, whereas
blocking of DR5 was less efficient in these cells. In line with
DNA fragmentation, activation of downstream signaling
cascades activated upon TRAIL treatment was strongly in-
hibited only after blocking DR4. These results prove the
dominant role of DR4 in melanoma cells, once it is ex-
pressed. Thus, TRAIL-induced apoptosis in melanoma cells
can be mediated by DR5, but DR4 signaling seemed to be
faster and more effective.
Standard anticancer therapies as various chemothera-
pies so far have achieved only limited success for me-
lanoma. New, more powerful strategies may be provided by
triggering proapoptotic pathways such as by TRAIL-medi-
ated cell death (Fischer and Schulze-Osthoff, 2005). The
combination of TRAIL with chemotherapy or radiotherapy
has been demonstrated as highly effective in several in vivo
Figure 7
Significant expression of both TRAIL
death receptors in melanoma biopsies.
The expression level of death receptor
4 (DR4) and death receptor 5 (DR5) was
examined by immunohistochemistry in
primary tumors from 40 patients with nod-
ular or superficial-spreading melanoma.
Three examples are shown (left side) with
strong expression of both receptors (pa-
tient A), strong expression of DR4, and
weak expression of DR5 (patient B), as
well as with missing expression of DR4
and strong expression of DR5 (patient C).
Immunocytochemistry for melanoma cell
lines A-375, SK-Mel-13, and SK-Mel-23
shown on the right side proved the
specificity of the antibodies applied and
demonstrated a comparable situation
in vitro and in vivo with respect to re-
ceptor expression. Negative controls for
immunohistochemistry and for immuno-
cytochemistry (no primary antibody) as
well as magnification scales are indicated
below.
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models, leading to complete eradication of human tumor
xenografts from colon, breast, lung, and prostate cancer
(Naka et al, 2002; Singh et al, 2003; Shankar et al, 2005).
The therapeutic effect coincided with induction of apopto-
sis, increased expression of Bax and Bak, as well as of DR4
and DR5 (Naka et al, 2002; Shankar et al, 2005). Specific
targeting of death receptors by selective agonistic mono-
clonal antibodies may provide an even more effective ap-
proach than TRAIL itself, as their activity may not be inter-
cepted by decoy receptors (Yagita et al, 2004). Based on the
promising results of preclinical studies, agonistic monoclon-
al antibodies to DR4 and DR5 have already been enrolled in
clinical trials for different tumors, however, so far not re-
ported for melanoma (Fischer and Schulze-Osthoff, 2005).
The ambiguity regarding the functionality of TRAIL re-
ceptors may have prevented the development of such
strategies for melanoma. Despite positive findings in im-
mune-incompetent mice, where the growth of melanoma
xenografts could be significantly reduced by combined
treatment with TRAIL and chemotherapies (Chawla-Sarkar
et al, 2003; Nyormoi et al, 2003), there were also several
reports that did not support TRAIL-based strategies for
melanoma. For instance, only a weak expression of TRAIL
death receptors was found in melanoma primary cultures
seen also in relation to weak responsiveness of these cul-
tures (Nguyen et al, 2001; Zhang et al, 2004). Especially
DR4 has not been regarded as a main effector for TRAIL-
mediated apoptosis in melanoma (Zhang et al, 1999, 2004;
Hersey and Zhang, 2001).
Strongly supporting the significance of our in vitro data,
here we show, significant expression of both DR4 as well as
of DR5 in the majority of melanoma sections, thus indicating
that efficient DR4 signaling seen in vitro may also be char-
acteristic for melanomas in vivo. In conclusion, expression
of TRAIL receptors and high efficiency of DR4-mediated
apoptosis in melanoma may be suggestive of a reassess-
ment of the suitability of TRAIL and especially of DR4-based
strategies in future melanoma therapies.
Materials and Methods
Cell culture In this study, seven human melanoma cell lines have
been used: A-375 (Giard et al, 1973), Mel-HO (Holzmann et al,
1988), SK-Mel-13, SK-Mel-19, SK-Mel-23 (Carey et al, 1976),
MeWo (Bean et al, 1975), and Mel 2a (Bruggen et al, 1981). Cell
lines were maintained in DMEM (4.5 g per L glucose; Invitrogen,
Karlsruhe, Germany) supplemented with 10% fetal calf serum and
antibiotics (Biochrom, Berlin, Germany). A-375/mock and A-375/
Bcl-2 as well as MelHO/mock and MelHO/Bcl-2 were established
by transfection of A-375 and Mel-HO, respectively, with either
pIRES plasmid (Clontech, Palo Alto, California) or with a pIRES
construct including a full-length cDNA for mouse Bcl-2 (pIRES-Bcl-
2), as described previously (Raisova et al, 2001). The tetracycline-
regulatable melanoma cell line SKM-13-Tet-On derived from stable
transfection of pTet-On plasmid (Clontech) into SK-Mel-13 me-
lanoma cells described previously (Eberle et al, 2003). Stable SKM-
13-Bcl-xL and SKM-13-mock cell clones derived from transfection
of SKM-13-Tet-On with pTRE-Bcl-xL and pTRE-1 (Clontech), re-
spectively (Hossini et al, 2003). Expression was induced in these
cells by 2 mg per mL doxycycline.
Several distinct cultures of normal human melanocytes (NHM)
were established from different foreskins by trypsin digestion, and
were cultivated as described previously in serum-free melanocyte
growth medium (Eberle et al, 1999).
For induction of apoptosis, KillerTRAIL (soluble, human, re-
combinant; Alexis, Gruenberg, Germany ALX-201-073-C020) was
used in concentrations of 20 and 100 ng per mL. Cells were seed-
ed in six-well plates (2  105 cells per well), and growth medium
was replaced after 24 h by 1 mL medium containing TRAIL. Block-
ing experiments were performed in 24-well plates (5  104 cells
per well). Cells were incubated for 24 h before addition of new
growth medium (0.25 mL) containing 10 mg per mL of the res-
pective blocking antibodies: mouse monoclonal TRAIL-R1/DR4
(Alexis, clone HS101, ALX-804-297-C100) or mouse monoclonal
TRAIL-R2/DR5 (Alexis, clone HS 201, ALX-804-298-100). TRAIL
(20 ng per mL) was added 1 h later, and incubation was continued
for another 6 h.
Transient transfection For overexpression of DR4 and DR5, re-
spectively, SK-Mel-13 melanoma cells were transiently transfected
with pCMV-SPORT6-DR4 or pCMV-SPORT6-DR5 (RZPD, Berlin,
Germany) containing full-length cDNA copies of the respective re-
ceptor. For overexpression of Bcl-2, SK-Mel-13 melanoma cells
were transiently transfected with pIRES-Bcl-2 (Raisova et al, 2001)
according to transfection protocols described previously (Eberle
et al, 2003). In brief, cells were seeded into six-well plates with
2  105 cells per well. The next day, cells at a confluence of 50%
were washed with serum-free Opti-MEM medium (Invitrogen) fol-
lowed by 4 h incubation at 371C with 1 mL per well of the respec-
tive transfection solution. Subsequently, cells were incubated for
additional 48 h in their respective growth medium, before analysis.
Transfection solutions contained 1 mL DMRIE-C lipid (Invitrogen)
and 0.1 mg, respectively, 0.2 mg plasmid per 1 mL in Opti-MEM.
Quantiﬁcation of apoptosis and cytotoxicity Apoptosis and
cytotoxicity assays were performed after incubation of cells for 6,
24, or 48 h in the presence of TRAIL. Apoptosis was quantified with
a cell death detection ELISA (Roche Diagnostics, Mannheim, Ger-
many), which detects mono- and oligonucleosomes formed in
apoptotic cells. In parallel, relative cytotoxicity levels were deter-
mined by measuring LDH activity in culture fluids using a cytotox-
icity detection system (Roche). Protocols for applying both assays
were described by us previously (Wieder et al, 1998). The relative
apoptosis and cytotoxicity rates determined after treatment with
TRAIL were calculated with respect to untreated control cells.
Flow cytometry For determination of DR4 and DR5 surface ex-
pression, cells were harvested from culture plates by treatment
with 0.02% EDTA in PBS. After washing with PBS, aliquots of
5  105 cells in 100 mL PBS, 1% BSA were incubated for 30 min
with mAb against TRAIL-R1/DR4 (Alexis, HS101, 1:100) or with
mAb against TRAIL-R2/DR5 (Alexis, clone HS 201, 1:100), respec-
tively. The isotypic monoclonal mouse IgG1 antibody (Alexis, clone
MOPC31C, 278-010, 1:100) was used as a negative control. After
washing cells two times with PBS, they were incubated for 30 min
with the secondary phycoerythrin-labeled goat anti-mouse IgG1
antiserum (Alexis, 211-201-C050; 1:100). Cells were again washed
with PBS, and surface expression was determined with a FACS-
Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany).
The mean fluorescence index was calculated by using CellQuest
software (Becton Dickinson).
Western blot analyses For protein extraction, cells at a conflu-
ence of 60%–80% were washed with PBS and were then imme-
diately lysed in the culture flask. Lysis buffer for DR4 and DR5: 10
mM Tris-HCl, pH 7.5, 144 mM NaCl, 1% Nonidet P-40, 0.5% SDS,
1 mM EDTA, 2 mM PMSF, 10 mg per mL trasylol (Bayer, Leverku-
sen, Germany), 20 mM leupeptin, 10 mM pepstatin. Lysis buffer for
caspases, BID, DFF45, and XIAP: 50 mM PIPES/HCl, pH 6.5, 2 mM
EDTA, 0.1% Chaps, 40 mM leupeptin, 15 mM pepstatin, 10 mg per
mL trasylol, 5 mM DTT (New England Biolabs, Frankfurt, Germany).
Cell lysates were homogenized and centrifuged for 5 min at
10,000  g. Equal protein amounts were separated by elect-
rophoresis under reducing conditions on 12% SDS-polyacrylamide
(PAGE) gels in parallel with a broad-range prestained SDS-PAGE
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protein standard (BioRad, Mu¨nchen, Germany). Protein quantifi-
cation, protein transfer, Ponceau staining, and immunodetection
were performed as detailed previously (Fecker et al, 2002).
The following antibodies were used for immunodetection:
TRAIL-R1/DR4 (Acris Antibodies, Hiddenhausen, Germany,
ab8414, 1:500), TRAIL-R2/DR5 (Acris Antibodies, ab8416, 1:500),
caspase-8 (New England Biolabs, Frankfurt, Germany, 9746,
1:1000); caspase-10 (clone 4C1, MBL International, Watertown,
MA, M059-3, 1:1000), BID (New England Biolabs, 2002, 1:1000);
caspase-9 (New England Biolabs, 9502, 1:1000); caspase-3 (New
England Biolabs, 9661, 1:1000); caspase-7 (New England Biolabs,
9492, 1:1000); DFF45 (New England Biolabs, 9731, 1:250); XIAP
(New England Biolabs, 2042, 1:1000); and Bcl-2 (Santa Cruz Bio-
technology, Germany, sc-509, 1:200), Bcl-x (Santa Cruz, S-18, sc-
634, 1:200), b-actin (clone AC-15, Sigma-Aldrich, A-5441, 1:10000).
As secondary antibodies, horseradish peroxidase-labeled goat an-
ti-rabbit immunoglobulins or goat anti-mouse immunoglobulins
(Dako Cytomation, Hamburg, Germany, 1:5000) were used.
Immunohistochemistry and immunocytochemistry Immuno-
histochemistry was performed on formalin-fixed and paraffin-
embedded archival tissue. Tumors were excised as a routine
treatment of patients, investigations were performed retrospec-
tively, and did not have any consequence for patients’ treatment.
Melanoma sections of 4–6 mm thickness were fixed on SuperFrost
plus slides (Roth, Karlsruhe, Germany) by incubation for 4 h at
601C followed by overnight incubation at 371C. After removal of
paraffin by xylol extractions, sections were rehydrated and finally
equilibrated in TRIS-buffered saline, pH 7.5 (TBS). For antigen re-
trieval, sections were boiled for 3 min in sodium citrate buffer (10
mM, pH 6) using a pressure cooker.
Cytospins were prepared after detachment of adherent cells by
incubation with 0.02% EDTA in PBS. Cells were washed 2  with
PBS at 41C, and aliquots of 30,000 cells were transferred to Su-
perFrost plus slides (Roth) by centrifugation at 100  g for 5 min
(Shandon, Astmoore, UK). Slides were air-dried, and adherent cells
were fixed with 3% paraformaldehyde in PBS for 10 min at 41C,
followed by 2  washing in PBS for each 5 min and air-drying
again.
For immunostaining of tissue sections and of cytospins by the
alkaline phosphatase/anti-alkaline phosphatase method (APAAP),
slides were firstly equilibrated with TBS for 5 min at room temper-
ature. Slides were then incubated in a humidity chamber at room
temperature with the following solutions: (1) protein blocking so-
lution (DakoCytomation, Hamburg, Germany) for 30 min; (2) pri-
mary antibody solution in antibody diluent (DakoCytomation) for 60
min: TRAIL-R1/DR4 rabbit polyclonal (Acris Antibodies, ab8414,
1:150), respectively, TRAIL-R2/DR5 (Acris Antibodies, ab8416,
1:100); (3) mouse anti-rabbit antibody solution (Dako, M0737) for
30 min, diluted 1:200 in HUSE (87.5% RPMI medium supplement-
ed with 10% heat inactivated FCS, 12.5% human serum); (4) rabbit
anti-mouse antibody solution for 30 min (DakoCytomation, Z0259),
diluted 1:20 in HUSE; and (5) APAAP complex (DakoCytomation,
D0651) for 30 min, diluted 1:50 in RPMI medium supplemented
with 10% heat-inactivated FCS. For cytospins, incubation steps 3
and 4 were repeated once, each for 10 min. Between two incu-
bation steps, slides were rinsed with TBS, 0.1% Tween 20, pH 7.5.
Slides were then stained for 15 min with the fuchsin substate-
chromogen system (DakoCytomation, K0624). After washing with
H2O, slides were counterstained for 30 s with Mayer’s hematoxylin
(Merck, Darmstadt, Germany). After again washing with H2O, slides
were covered with Aquamount (BDH Laboratory Supplies, Poole,
England). Microscopical evaluation was based on estimating the
percentage of cells with strong, medium, weak, or no staining.
Cells with strong or medium staining were considered as positive.
Statistics and general statements Assays consisted of duplicate
or triplicate values, and at least three independent experiments
were performed. The mean values and standard deviations were
calculated from these three independent experiments.
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